2. Search Result
Search Result
Results for "

Huntington'schorea

" in MedChemExpress (MCE) Product Catalog:

63

Inhibitors & Agonists

2

Screening Libraries

2

Fluorescent Dye

3

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147060
    Dyrk1A-IN-3

    		DYRK Neurological Disease
    Dyrk1A-IN-3 (Compound 8b), a highly selective  dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC50=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease .
    Dyrk1A-IN-3
  • HY-108312A
    AC-VEID-CHO TFA

    		Caspase Neurological Disease
    AC-VEID-CHO (TFA) is a peptide-derived caspase inhibitor and has potency of inhibition for Caspase-6, Caspase-3 and Caspase-7 with IC50 values of 16.2 nM, 13.6 nM and 162.1 nM, respectively. AC-VEID-CHO (TFA) can be used for the research of neurodegenerative conditions including Alzheimer’s and Huntington’s disease .
    AC-VEID-CHO TFA
  • HY-B0349
    Meclizine dihydrochloride
    2 Publications Verification

    Meclozine dihydrochloride

    		 Histamine Receptor Apoptosis Neurological Disease Endocrinology Cancer
    Meclizine (Meclozine) dihydrochloride, an antihistamine, reversibly inhibits the interaction of histamine at the H1 receptors. Meclizine dihydrochloride is a member of the piperazine class of H1 antagonists. Meclizine dihydrochloride is an effective anti-motion sickness agent. Meclizine dihydrochloride crosses the blood-brain barrier. Meclizine dihydrochloride can be used for the research of polyQ toxicity disorders, such as Huntington's disease. Meclizine dihydrochloride is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for Human CAR .
    Meclizine dihydrochloride
  • HY-132593A
    Rovanersen sodium

    WVE-120101 sodium

    		 Huntingtin Neurological Disease
    Rovanersen sodium is an antisense oligonucleotide that specifically targets mutated mRNA copies of the huntington (HTT) gene without affecting healthy mRNA of HTT gene, thereby preventing the production of faulty Huntingtin protein. Rovanersen sodium can be used for huntington’s disease research .
    Rovanersen sodium
  • HY-W019710
    (E,E)-RGFP966

    		HDAC Neurological Disease
    (E,E)-RGFP966 is a selective and CNS permeable HDAC3 inhibitor that can be used for the research of Huntington’s disease .
    (E,E)-RGFP966
  • HY-122958
    Peucedanocoumarin III

    		α-synuclein Neurological Disease
    Peucedanocoumarin III is an inhibitor of α-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .
    Peucedanocoumarin III
  • HY-B0349A
    Meclizine

    Meclozine

    		 Histamine Receptor Apoptosis Neurological Disease Inflammation/Immunology
    Meclizine (Meclozine), an antihistamine, reversibly inhibits the interaction of histamine at the H1 receptors. Meclizine is a member of the piperazine class of H1 antagonists. Meclizine is an effective anti-motion sickness agent. Meclizine crosses the blood–brain barrier. Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for Human CAR. Meclizine can be used for the research of polyQ toxicity disorders, such as Huntington's disease .
    Meclizine
  • HY-B0349B
    Meclizine dihydrochloride monohydrate

    Meclozine dihydrochloride monohydrate

    		 Histamine Receptor Apoptosis Neurological Disease Inflammation/Immunology
    Meclizine (Meclozine) dihydrochloride monohydrate, an antihistamine, reversibly inhibits the interaction of histamine at the H1 receptors. Meclizine dihydrochloride is a member of the piperazine class of H1 antagonists. Meclizine dihydrochloride monohydrate is an effective anti-motion sickness agent. Meclizine dihydrochloride monohydrate crosses the blood-brain barrier. Meclizine dihydrochloride monohydrate is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for Human CAR. Meclizine dihydrochloride monohydrate can be used for the research of polyQ toxicity disorders, such as Huntington's disease .
    Meclizine dihydrochloride monohydrate
  • HY-B0349R
    Meclizine (dihydrochloride) (Standard)

    		Histamine Receptor Apoptosis Neurological Disease Endocrinology Cancer
    Meclizine (dihydrochloride) (Standard) is the analytical standard of Meclizine (dihydrochloride). This product is intended for research and analytical applications. Meclizine (Meclozine) dihydrochloride, an antihistamine, reversibly inhibits the interaction of histamine at the H1 receptors. Meclizine dihydrochloride is a member of the piperazine class of H1 antagonists. Meclizine dihydrochloride is an effective anti-motion sickness agent. Meclizine dihydrochloride crosses the blood-brain barrier. Meclizine dihydrochloride can be used for the research of polyQ toxicity disorders, such as Huntington's disease. Meclizine dihydrochloride is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for Human CAR .
    Meclizine (dihydrochloride) (Standard)
  • HY-119274
    BN-82451 dihydrochloride

    		Others Neurological Disease
    BN-82451 dihydrochloride, an orally active and CNS-penetrated antioxidant and a multitargeting neuroprotective agent, exert a significant protection in experimental animal models mimicking aspects of cerebral ischemia, Parkinson disease, Huntington disease, and more particularly amyotrophic lateral sclerosis .
    BN-82451 dihydrochloride
  • HY-132593
    Rovanersen

    WVE-120101

    		 Huntingtin Neurological Disease
    Rovanersen (WVE-120101) is an antisense oligonucleotide that specifically targets mutated mRNA copies of the huntington (HTT) gene without affecting healthy mRNA of HTT gene, thereby preventing the production of faulty Huntingtin protein. Rovanersen can be used for huntington’s disease research .
    Rovanersen
  • HY-107660
    SIRT2-IN-8

    		Sirtuin Neurological Disease
    SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research .
    SIRT2-IN-8
  • HY-137207
    MK-28
    5 Publications Verification

    		 PERK Neurological Disease
    MK-28 is a potent and selective PERK activator. MK-28 exhibits remarkable pharmacokinetic properties and high BBB penetration in mice .
    MK-28
  • HY-156650
    Votoplam

    		DNA/RNA Synthesis Neurological Disease
    Votoplam is a gene splicing modulator, used to inhibit Huntington's disease .
    Votoplam
  • HY-15262
    SRT 2104
    10+ Cited Publications

    		 Sirtuin Neurological Disease Metabolic Disease Cancer
    SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD + dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington’s disease .
    SRT 2104
  • HY-G0025
    Tetrabenazine Metabolite

    (-)-β-Dihydrotetrabenazine; (-)-β-HTBZ

    		 Monoamine Transporter Drug Metabolite Neurological Disease
    Tetrabenazine Metabolite is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite is a vesicular monoamine transporter 2 (VMAT2) inhibitor with a high affinity (Ki=13.4 nM) . Tetrabenazine Metabolite is be developed for the treatment of chorea associated with Huntington’s disease and other hyperkinetic disorders .
    Tetrabenazine Metabolite
  • HY-150640
    Rho-Kinase-IN-2

    		ROCK Neurological Disease
    Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC50=3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research .
    Rho-Kinase-IN-2
  • HY-132579A
    Tominersen sodium

    RG6042 sodium; IONIS-HTTRx sodium

    		 Huntingtin Neurological Disease
    Tominersen sodium is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen sodium can be used for the research of Huntington’s disease (HD) .
    Tominersen sodium
  • HY-47822
    WAY-354574

    		Sirtuin Neurological Disease
    WAY-354574 is an active molecule targeting deacetylase (Sirtuin) for the study of Huntington's disease (HD) .
    WAY-354574
  • HY-132579
    Tominersen

    RG6042; IONIS-HTTRx

    		 Huntingtin Neurological Disease
    Tominersen (RG6042) is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen can be used for the research of Huntington’s disease (HD) .
    Tominersen
  • HY-134145
    1-(Anilinocarbonyl)proline

    		Fluorescent Dye Neurological Disease
    1-(Anilinocarbonyl)proline can be used to identify dual action probes in a cell model of Huntington .
    1-(Anilinocarbonyl)proline
  • HY-163806
    NT376

    		HDAC Neurological Disease Cancer
    NT376 is a high potency and selectivity inhibitor of class-IIa Histone deacetylases (HDAC) with an IC50 value of 32 nM, similar to NT160 (HY-149285) (IC50= 46 nM) in HT-29 cells. NT376 is proming for research of various cancers and in the diseases of the central nervous system (CNS) such as Alzheimer’s and Huntington’s diseases .
    NT376
  • HY-150236
    FITC-labeled Tominersen sodium

    		Huntingtin Neurological Disease
    FITC-labeled Tominersen (sodium) is the Tominersen labeled with FITC. Tominersen (RG6042) is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen can be used for the research of Huntington’s disease (HD).
    FITC-labeled Tominersen sodium
  • HY-143218
    TPE-MI
    3 Publications Verification

    Tetraphenylethene maleimide

    		 Huntingtin Parasite Neurological Disease
    TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells. TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .
    TPE-MI
  • HY-108312
    AC-VEID-CHO

    		Caspase Neurological Disease
    AC-VEID-CHO is a peptide-derived caspase inhibitor and has potency of inhibition for Caspase-6, Caspase-3 and Caspase-7 with IC50 values of 16.2 nM, 13.6 nM and 162.1 nM, respectively. AC-VEID-CHO also inhibits VEIDase activity an IC50 value of 0.49 µM. AC-VEID-CHO can be used for the research of neurodegenerative conditions including Alzheimer’s and Huntington’s disease .
    AC-VEID-CHO
  • HY-136311
    NCT-504

    		Others Neurological Disease
    NCT-504 is a selective allosteric inhibitor of PIP4Kγ, with an IC50 of 15.8 μM. NCT-504 is potential for the research of Huntington's disease .
    NCT-504
  • HY-147233
    MIND4-19

    		Sirtuin Neurological Disease
    MIND4-19 is a potent SIRT2 inhibitor with an IC50 value of 7.0 μM. MIND4-19 can be used for researching Huntington's disease .
    MIND4-19
  • HY-136833
    X5050

    		Others Neurological Disease
    X5050 is a REST inhibitor, with an EC50 of 2.1 μM .
    X5050
  • HY-A0198
    Adinazolam

    U 41123

    		 GABA Receptor Neurological Disease
    Adinazolam (U 41123) is a benzodiazepine agonist. Adinazolam, a triazolobenzodiazepine, has dual anxiolytic and antidepressant activities .
    Adinazolam
  • HY-A0198A
    Adinazolam mesylate

    U 41123F mesylate

    		 GABA Receptor Neurological Disease
    Adinazolam mesylate (U 41123) is a benzodiazepine agonist. Adinazolam mesylate, a triazolobenzodiazepine, has dual anxiolytic and antidepressant activities .
    Adinazolam mesylate
  • HY-15452
    Selisistat
    Maximum Cited Publications
    193 Publications Verification

    EX-527

    		 Sirtuin Inflammation/Immunology Cancer
    Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC50 of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease .
    Selisistat
  • HY-B0590
    Tetrabenazine

    Ro 1-9569

    		 Monoamine Transporter Neurological Disease
    Tetrabenazine (Ro 1-9569) is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .
    Tetrabenazine
  • HY-B0590E
    Tetrabenazine mesylate

    Ro 1-9569 mesylate

    		 Monoamine Transporter Neurological Disease
    Tetrabenazine (Ro 1-9569) mesylate is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine mesylate can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .
    Tetrabenazine mesylate
  • HY-161163
    IND 1316

    		AMPK Neurological Disease
    IND 1316 is an orally active, blood-brain barrier permeable AMPK activator with neuroprotective effects in animal models of Huntington's disease. IND 1316 can be used for research on neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .
    IND 1316
  • HY-125172
    PolyQ aggregation inhibitor C2-8

    Polyglutamine Aggregation inhibitor III

    		 Others Others
    C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.
    PolyQ aggregation inhibitor C2-8
  • HY-N2099
    Onjisaponin B

    		Autophagy Neurological Disease
    Onjisaponin B is a natural product derived from Polygala tenuifolia. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells, and exbibits potential therapeutic effects on Parkinson disease and Huntington disease .
    Onjisaponin B
  • HY-150245
    mHTT-IN-1

    		Huntingtin Neurological Disease
    mHTT-IN-1 (Example 1) is a potent mutant huntingtin (mHTT) inhibitor. mHTT is toxic and a major cause of the inherited autosomal dominant neurodegenerative disorder, Huntington's disease (HD). mHTT-IN-1 conducts the reduction of mHTT with an EC50 value of 46 nM .
    mHTT-IN-1
  • HY-16771
    Valbenazine
    3 Publications Verification

    NBI-98854

    		 Monoamine Transporter Neurological Disease
    Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM .
    Valbenazine
  • HY-16771A
    Valbenazine tosylate

    NBI-98854 tosylate

    		 Monoamine Transporter Neurological Disease
    Valbenazine tosylate (NBI-98854 tosylate) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM .
    Valbenazine tosylate
  • HY-P6374
    IIQLPEIVVV TFA

    		Dynamin Neurological Disease
    IIQLPEIVVV TFA is a specific inhibitor of Drp1-Mff interaction. IIQLPEIVVV TFA can distinguish physiological from pathological fission and block physiological fission, thus leading to mitochondrial dysfunction. IIQLPEIVVV TFA can be used in the study of Huntington's disease .
    IIQLPEIVVV TFA
  • HY-153427
    Tau protein aggregation-IN-1

    		Tau Protein Neurological Disease
    Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .
    Tau protein aggregation-IN-1
  • HY-160604
    Remacemide

    FPL 12924; PR 934-423; FPL 13592

    		 iGluR Neurological Disease
    Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research .
    Remacemide
  • HY-124476
    Cystamine

    		Caspase Glutaminase Apoptosis Cancer
    Cystamine is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .
    Cystamine
  • HY-W020050
    Cystamine dihydrochloride

    		Caspase Glutaminase Apoptosis Neurological Disease Cancer
    Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .
    Cystamine dihydrochloride
  • HY-128477
    AUTEN-67 inner salt

    Autophagy enhancer-67 inner salt

    		 Autophagy Neurological Disease
    AUTEN-67 (inner salt), the inner salt form of AUTEN-67 (HY-117924), is an orally active autophagy-enhancing agent and MTMR14 inhibitor with potent antiaging and neuroprotective effects. AUTEN-67 (inner salt) hampers the progression of neurodegenerative symptoms in a drosophila model of Huntington's disease .
    AUTEN-67 inner salt
  • HY-B0590R
    Tetrabenazine (Standard)

    		Monoamine Transporter Neurological Disease
    Tetrabenazine (Standard) is the analytical standard of Tetrabenazine. This product is intended for research and analytical applications. Tetrabenazine (Ro 1-9569) is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .
    Tetrabenazine (Standard)
  • HY-16482
    Teglicar

    		Endogenous Metabolite Neurological Disease Metabolic Disease
    Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) .
    Teglicar
  • HY-B1899
    Taurodeoxycholic acid
    3 Publications Verification

    		 Endogenous Metabolite Apoptosis Neurological Disease
    Taurodeoxycholic acid, a bile acid, stabilizes the mitochondrial membrane, decreases free radical formation. Taurodeoxycholic acid inhibits apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid exhibits neuroprotective effect in 3-nitropropionic acid induced mouse model or genetic mouse model of Huntington's disease (HD) .
    Taurodeoxycholic acid
  • HY-12542
    Dantrolene
    5+ Cited Publications

    F 368

    		 Calcium Channel Autophagy Neurological Disease Inflammation/Immunology
    Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene is a direct-acting skeletal muscle relaxant. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome .
    Dantrolene
  • HY-143792
    HTT-D3

    		P-glycoprotein Neurological Disease
    HTT-D3 is a potent and orally active huntingtin (HTT) splicing modulator. HTT-D3 acts by promoting the inclusion of a pseudoexon containing a premature termination codon (stop-codon psiExon), leading to HTT mRNA degradation and reduction of HTT levels. HTT-D3 reduces p-glycoprotein (P-gp) efflux, and can be uesd for Huntington's disease research .
    HTT-D3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: